New combo therapy aims to slow liver cancer progression in tough cases

NCT ID NCT07187284

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 20 times

Summary

This study tests whether adding a procedure called endovascular denervation (EDN) to standard treatments (TACE/HAIC plus immune-targeted therapy) can help people with advanced liver cancer that has spread to the portal vein and has not responded to initial therapy. About 62 adults aged 18-75 will be randomly assigned to receive either the standard treatment alone or the standard treatment plus EDN. The goal is to see if the combination improves how long the cancer stays under control in the liver and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zhongda Hospital Affiliated to Southeast University, Department of Interventional and Vascular Surgery

    Nanjing, Jiangsu, 210009, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.